While key survival pathways (JAK2/STAT3, PI3K/Akt, and MAPK) remained relatively unaffected, SD2-2305 modulated growth factor receptors post-transcriptionally, decreasing HER2/ErbB2 and increasing TGF-beta receptor 1 expression. Collectively, these findings demonstrate that the DRD2 antagonist SD2-2305 exerts potent anticancer effects through the induction of cell cycle arrest and apoptosis, and suggest that the anticancer activity of SD2-2305 is associated with coordinated modulation of growth factor receptor signaling and cell-cycle regulators in CRC cells.

P=N/A, N=44, Completed, Hasanuddin University

P=N/A, N=104, Recruiting, Eastern Health | Not yet recruiting --> Recruiting

The case shows the significance of following prolactin levels in children who are on risperidone therapy particularly those who are non-verbal or those who cannot communicate any discomfort. Clinicians are to remember that risperidone leads to hyperprolactinemia which can simulate pituitary malfunctions. Early identification, educating caregivers, and substitution of prolactin-stimulating drugs with prolactin-sparing ones like olanzapine will allow avoiding unnecessary investigations and enhancing the clinical and family outcomes.

P2, N=57, Not yet recruiting, Fiona Stanley Hospital

Aims of the study were to: 1) test the effects of SF3B1 inhibitor pladienolide B in tumoral lactotroph cells expressing wild-type or mutated SF3B1R625H; 2) investigate SF3B1 impact on tumoral cells responsiveness to DRD2 agonist cabergoline...Indeed, SF3B1 inhibitor pladienolide B exerted antitumoral actions in PRL-PitNET cells bearing wild-type or mutated SF3B1. Moreover, both SF3B1R625H overexpression and SF3B1 genetic silencing reduced DRD2 expression and signaling.

P2, N=216, Not yet recruiting, First Affiliated Hospital of Zhejiang University

Through structure-based virtual screening, our results suggest that Ziprasidone and Apomorphine may disrupt the BARD1-XRCC5 interaction...Our findings unveil a novel LLPS-mediated mechanism by which BARD1 confers TMZ resistance in GBM, positioning it as a prognostic marker and a therapeutic target. Targeting the BARD1-XRCC5 axis presents a promising strategy to overcome chemoresistance.

By utilizing FDA-approved DRD2 agonists as functional probes, clinicians can implement a dopaminergic challenge to identify windows of maximal VEGF-dependency via dynamic imaging. This approach transforms anti-angiogenic interventions from empirical into a precision theranostic platform, enabling real-time assessment of tumor VEGF-dependency and rational treatment selection that maximizes efficacy while minimizing toxicity.

Together, these findings indicate that acute treatment with risperidone in male mice exerts pronounced molecular effects in medial and ventral forebrain regions with high oligodendrocyte and glial cell abundance. Moreover, enrichment analysis points to a molecular convergence between risperidone-induced transcription and genetic pathways implicated in schizophrenia.

P2/3, N=110, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Dec 2028

P3, N=100, Recruiting, Blokhin's Russian Cancer Research Center